FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111066965> ?p ?o ?g. }

• W2111066965 endingPage "33" @default.
• W2111066965 startingPage "25" @default.
• W2111066965 abstract "Platelet activation causes conformational changes of integrin GPIIb/IIIa (α IIb β 3 ), resulting in the exposure of its ligand-binding pocket. This provides the unique possibility to design agents that specifically block activated platelets only. We used phage display of single-chain antibody (scFv) libraries in combination with several rounds of depletion/selection to obtain human scFvs that bind specifically to the activated conformation of GPIIb/IIIa. Functional evaluation of these scFv clones revealed that fibrinogen binding to human platelets and platelet aggregation can be effectively inhibited by activation-specific scFvs. In contrast to clinically used GPIIb/IIIa blockers, which are all conformation unspecific, activation-specific GPIIb/IIIa blockers do not induce conformational changes in GPIIb/IIIa or outside-in signaling, as evaluated by ligand-induced binding-site (LIBS) exposure in flow cytometry or P-selectin expression in immunofluorescence microscopy, respectively. In contrast to the conformation-unspecific blocker abciximab, activation-specific scFvs permit cell adhesion and spreading on immobilized fibrinogen, which is mediated by nonactivated GPIIb/IIIa. Mutagenesis studies and computer modeling indicate that exclusive binding of activation-specific scFv is mediated by RXD motifs in the heavy-chain complementary-determining region (CDR) 3 of the antibodies, which in comparison with other antibodies forms an exceptionally extended loop. In vivo experiments in a ferric-chloride thrombosis model of the mouse carotid artery demonstrate similar antithrombotic potency of activation-specific scFv, when compared with the conformation-unspecific blockers tirofiban and eptifibatide. However, in contrast to tirofiban and eptifibatide, bleeding times are not prolonged with the activation-specific scFvs, suggesting lower bleeding risks. In conclusion, activation-specific GPIIb/IIIa blockade via human single-chain antibodies represents a promising novel strategy for antiplatelet therapy." @default.
• W2111066965 created "2016-06-24" @default.
• W2111066965 creator A5017098029 @default.
• W2111066965 creator A5021325357 @default.
• W2111066965 creator A5029866787 @default.
• W2111066965 creator A5032884807 @default.
• W2111066965 creator A5038996491 @default.
• W2111066965 creator A5044212481 @default.
• W2111066965 creator A5049936296 @default.
• W2111066965 creator A5057620634 @default.
• W2111066965 creator A5058650782 @default.
• W2111066965 creator A5068289720 @default.
• W2111066965 creator A5068359313 @default.
• W2111066965 creator A5070752593 @default.
• W2111066965 creator A5085563251 @default.
• W2111066965 date "2006-07-07" @default.
• W2111066965 modified "2023-10-11" @default.
• W2111066965 title "Conformation-Specific Blockade of the Integrin GPIIb/IIIa" @default.
• W2111066965 cites W1555561206 @default.
• W2111066965 cites W1589100498 @default.
• W2111066965 cites W1601529928 @default.
• W2111066965 cites W1834731714 @default.
• W2111066965 cites W1979498341 @default.
• W2111066965 cites W1985370576 @default.
• W2111066965 cites W1989381306 @default.
• W2111066965 cites W2001733286 @default.
• W2111066965 cites W2007046037 @default.
• W2111066965 cites W200838759 @default.
• W2111066965 cites W2011031332 @default.
• W2111066965 cites W2024623688 @default.
• W2111066965 cites W2025510606 @default.
• W2111066965 cites W2029147896 @default.
• W2111066965 cites W2029606950 @default.
• W2111066965 cites W2050701385 @default.
• W2111066965 cites W2063330553 @default.
• W2111066965 cites W2067836657 @default.
• W2111066965 cites W2080013283 @default.
• W2111066965 cites W2083733554 @default.
• W2111066965 cites W2092284194 @default.
• W2111066965 cites W2106264965 @default.
• W2111066965 cites W2133437250 @default.
• W2111066965 cites W2144886557 @default.
• W2111066965 cites W2273675591 @default.
• W2111066965 cites W2395047360 @default.
• W2111066965 cites W2022804094 @default.
• W2111066965 doi "https://doi.org/10.1161/01.res.0000232317.84122.0c" @default.
• W2111066965 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16778135" @default.
• W2111066965 hasPublicationYear "2006" @default.
• W2111066965 type Work @default.
• W2111066965 sameAs 2111066965 @default.
• W2111066965 citedByCount "171" @default.
• W2111066965 countsByYear W21110669652012 @default.
• W2111066965 countsByYear W21110669652013 @default.
• W2111066965 countsByYear W21110669652014 @default.
• W2111066965 countsByYear W21110669652015 @default.
• W2111066965 countsByYear W21110669652016 @default.
• W2111066965 countsByYear W21110669652017 @default.
• W2111066965 countsByYear W21110669652018 @default.
• W2111066965 countsByYear W21110669652019 @default.
• W2111066965 countsByYear W21110669652020 @default.
• W2111066965 countsByYear W21110669652021 @default.
• W2111066965 countsByYear W21110669652022 @default.
• W2111066965 countsByYear W21110669652023 @default.
• W2111066965 crossrefType "journal-article" @default.
• W2111066965 hasAuthorship W2111066965A5017098029 @default.
• W2111066965 hasAuthorship W2111066965A5021325357 @default.
• W2111066965 hasAuthorship W2111066965A5029866787 @default.
• W2111066965 hasAuthorship W2111066965A5032884807 @default.
• W2111066965 hasAuthorship W2111066965A5038996491 @default.
• W2111066965 hasAuthorship W2111066965A5044212481 @default.
• W2111066965 hasAuthorship W2111066965A5049936296 @default.
• W2111066965 hasAuthorship W2111066965A5057620634 @default.
• W2111066965 hasAuthorship W2111066965A5058650782 @default.
• W2111066965 hasAuthorship W2111066965A5068289720 @default.
• W2111066965 hasAuthorship W2111066965A5068359313 @default.
• W2111066965 hasAuthorship W2111066965A5070752593 @default.
• W2111066965 hasAuthorship W2111066965A5085563251 @default.
• W2111066965 hasBestOaLocation W21110669651 @default.
• W2111066965 hasConcept C126322002 @default.
• W2111066965 hasConcept C153911025 @default.
• W2111066965 hasConcept C159654299 @default.
• W2111066965 hasConcept C170493617 @default.
• W2111066965 hasConcept C185592680 @default.
• W2111066965 hasConcept C195616568 @default.
• W2111066965 hasConcept C195687474 @default.
• W2111066965 hasConcept C203014093 @default.
• W2111066965 hasConcept C2776335557 @default.
• W2111066965 hasConcept C2777871224 @default.
• W2111066965 hasConcept C2780400711 @default.
• W2111066965 hasConcept C2781056559 @default.
• W2111066965 hasConcept C2910542480 @default.
• W2111066965 hasConcept C3018697912 @default.
• W2111066965 hasConcept C45393284 @default.
• W2111066965 hasConcept C500558357 @default.
• W2111066965 hasConcept C55493867 @default.
• W2111066965 hasConcept C71924100 @default.
• W2111066965 hasConcept C86803240 @default.
• W2111066965 hasConcept C89560881 @default.

• next